What is COPD?
COPD (Chronic Obstructive Pulmonary Disease) is one of the most common lung diseases. It makes it difficult to breathe. There are two main forms of COPD:
~ Chronic Bronchitis, defined by long term cough with mucus
~Emphysema, defined by destruction of the lungs over time
Most people with COPD have a combination of both conditions.
Causes, incidence, and risk factors
Smoking is the leading cause of COPD. The more a person smokes, the more likely that person will develop COPD although some people smoke for years and never get COPD.
For more information see PubMed Health (part of the National Institutes of Health):
Our Current COPD Studies:
Below is a summary of our current trials, if you are interested in learning more, simply click on the trial's name to answer a few qualifying questions and request a contact by our research staff:
This study is to evaluate the effect of Fluticasone Furoate/Vilanterol
Inhalation Powder verses a Placebo in subjects with moderate COPD and a history or increased risk for Cardiovascular disease. Compensation for time and travel is available.
ROF07 COPD Study
To demonstrate the additional benefit of roflumilast added on to a fixed-dose combination LABA/ICS (Advair 250/50 1 puff bid or Symbicort 160/4.5 2 puffs bid) in the reduction of exacerbations in subjects with severe or very severe COPD who have had at least 2 documented flares of COPD in the last 12 months.
A6631033 COPD Study
A phase 2B, placebo controlled study to evaluate the efficacy and safety of once daily orally administered medication (PH-797804) for 12 weeks in adults with moderate to severe COPD. Compensation for time and travel available.
1222.51 COPD Study
A phase 3 study to assess the efficacy and safety of 12 weeks of daily inhaled olodaterol and tiotropium compared to daily inhaled tiotropium and placebo for individuals with chronic COPD. Is 1222.51 right for you? Fill out our brief questionnaire to see if you pre-qualify!
CQVA149A COPD Study
A 1 year study for current or ex-smokers age 40 or older with COPD involving moderate to severe airflow limitation. The trial will compare QVA149 to QAB149, both are study medications - i.e., there is no placebo in this study. Each person enrolled will receive no-cost study-related treatment for the duration of their involvement with the study. Interested? Fill out our questionnaire to see if you pre-qualify!